Re: Overall Survival of Men with Metachronous Metastatic Hormone-Sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy

被引：0

作者：

Sweeney, C. J.

Martin, A. J.

Stockler, M. R.

Begbie, S.

Chi, K. N.

Chowdhury, S.

Coskinas, X.

Frydenberg, M.

Hague, W. E.

Horvath, L. G.

Joshua, A. M.

Lawrence, N. J.

Marx, G. M.

McCaffrey, J.

McDermott, R.

McJannett, M.

North, S. A.

Parnis, F.

Parulekar, W.

Pook, D. W.

Reaume, M. N.

Sandhu, S. K.

Tan, A.

Tan, T. H.

Thomson, A.

Tu, E.

Vera-Badillo, F.

Williams, S. G.

Yip, S.

Zhang, A. Y.

Zielinski, R. R.

Davis, I. D.

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Harvard Med Sch, Boston, MA 02115 USA

[3] Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW, Australia

[4] Concord Repatriat Gen Hosp, Concord Canc Ctr, Concord, Australia

[5] Chris Obrien Lifehouse RPA, Sydney, NSW, Australia

[6] Port Macquarie Base Hosp, Port Macquarie, NSW, Australia

[7] Mid North Coast Canc Inst Port Macquarie, Port Macquarie, NSW, Australia

[8] BC Canc Agcy, Vancouver, BC, Canada

[9] Univ British Columbia, Vancouver, BC, Canada

[10] CRUK & Kings Coll London, Guys & St Thomas NHS Fdn Trust Biomed Res Ctr, London, England

[11] Sarah Cannon Res UK, London, England

[12] Monash Univ, Melbourne, Vic, Australia

[13] Australian Urol Associates, Melbourne, Vic, Australia

[14] St Vincents Hosp, Kinghorn Canc Ctr, Sydney, NSW, Australia

[15] Garvan Inst Med Res, Sydney, NSW, Australia

[16] Auckland City Hosp, Auckland, New Zealand

[17] Sydney Adventist Hosp, Wahroonga, Australia

[18] Canc Trials Ireland, Dublin, Ireland

[19] Mater Misericordiae Univ Hosp, Dublin, Ireland

[20] St Vincents Univ Hosp, Dublin, Ireland

[21] Univ Coll Dublin, Dublin, Ireland

[22] ANZUP Canc Trials Grp, Camperdown, NSW, Australia

[23] Cross Canc Inst, Edmonton, AB, Canada

[24] Univ Alberta, Edmonton, AB, Canada

[25] Adelaide Canc Ctr, Adelaide, SA, Australia

[26] Univ Adelaide, Adelaide, SA, Australia

[27] Queens Univ, Canadian Canc Trials Grp CCTG, Kingston, ON, Canada

[28] Monash Hlth, Melbourne, Vic, Australia

[29] Univ Ottawa, Ottawa, ON, Canada

[30] Ottawa Hosp Res Inst, Ottawa, ON, Canada

[31] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[32] Univ Melbourne, Melbourne, Vic, Australia

[33] Waikato Dist Hlth Board, Hamilton, New Zealand

[34] Royal Adelaide Hosp, Adelaide, SA, Australia

[35] Royal Cornwall Hosp, Truro, Cornwall, England

[36] Kingston Hlth Sci Ctr, Kingston, ON, Canada

[37] Macquarie Univ, Sydney, NSW, Australia

[38] Orange Hlth Serv, Cent West Canc Care Ctr, Orange, Australia

[39] Univ Western Sydney, Sydney, NSW, Australia

[40] Eastern Hlth, Melbourne, Vic, Australia

来源：

JOURNAL OF UROLOGY | 2021年 / 206卷 / 06期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1519 / 1520

页数：3

共 50 条

[41] Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses EDITORIAL COMMENT
Smoragiewicz, Martin
Emmenegger, Urban
JOURNAL OF UROLOGY, 2021, 205 (05): : 1370 - 1370
[42] Improved survival of men with metastatic prostate cancer treated with androgen deprivation therapy plus radiotherapy to the prostate
Yano, Akihiro
Kagawa, Makoto
Takeshita, Hideki
Okada, Yohei
Morozumi, Makoto
Kawakami, Satoru
INTERNATIONAL JOURNAL OF UROLOGY, 2017, 24 (12) : 863 - 865
[43] Overall survival with darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer in the phase 3 ARASENS trial
Todenhoefer, Tilman
Smith, Matthew R.
Hussain, Maha
Saad, Fred
Fizazi, Karim
Sternberg, Cora N.
Crawford, David
Kopyltsov, Evgeny
Park, Chandler H.
Alekseev, Boris
Pino, Alvaro Montesa
Ye, Dingwei
Parnis, Francis
Tammela, Teuvo
Suzuki, Hiroyoshi
Joensuu, Heikki
Thiele, Silke
Li, Rui
Kuss, Iris
Tombal, Bertrand
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 110 - 110
[44] Cardiovascular medications and overall survival in metastatic hormone-sensitive prostate cancer.
Pickett, Carley
Eaton, Daniel B.
Tohmasi, Steven
Karunanandaa, Krishny
Gopukumar, Deepika
Puri, Varun
Schoen, Martin W.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 75 - 75
[45] Transcriptional Profile Associated with Clinical Outcomes in Metastatic Hormone-Sensitive Prostate Cancer Treated with Androgen Deprivation and Docetaxel
Jimenez, Natalia
Reig, Oscar
Marin-Aguilera, Mercedes
Aversa, Caterina
Ferrer-Mileo, Laura
Font, Albert
Rodriguez-Vida, Alejo
Angel Climent, Miguel
Cros, Sara
Chirivella, Isabel
Domenech, Montserrat
Figols, Mariona
Gonzalez-Billalabeitia, Enrique
Jimenez Peralta, Daniel
Rodriguez-Carunchio, Leonardo
Garcia-Esteve, Samuel
Garcia de Herreros, Marta
Ribal, Maria J.
Prat, Aleix
Mellado, Begona
CANCERS, 2022, 14 (19)
[46] Time to Prostate-Specific Antigen Nadir Independently Predicts Overall Survival in Patients Who Have Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen-Deprivation Therapy Editorial Comment
Walsh, Patrick C.
JOURNAL OF UROLOGY, 2009, 182 (03): : 974 - 974
[47] Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone-sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study (vol 28, pg 765, 2021)
Iguchi, T.
Kimura, G.
Fukasawa, S.
INTERNATIONAL JOURNAL OF UROLOGY, 2021, 28 (10) : 1079 - 1079
[48] Phase 3 Study of Androgen Deprivation Therapy (ADT) with Enzalutamide (ENZA) or Placebo (PBO) in Metastatic Hormone-Sensitive Prostate Cancer (MHSPC): The Arches Trial
Horvath, Lisa
Armstrong, Andrew J.
Szmulewitz, Russell
Petrylak, Daniel
Villers, Arnauld
Azad, Arun
Alcaraz, Antonio
Alekseev, Boris
Iguchi, Taro
Shore, Neal D.
Rosbrook, Brad
Sugg, Jennifer
Baron, Benoit
Chen, Lucy
Stenzl, Arnulf
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 32 - 33
[49] Association of time from definitive therapy (DT) to start of androgen deprivation therapy (ADT) for metastatic disease and survival outcomes in men with new metastatic hormone-sensitive prostate cancer (mHSPC).
Gill, David Michael
Stenehjem, David D.
Cheng, Heather H.
Kessler, Elizabeth Riley
Hahn, Andrew W.
Gupta, Sumati
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
[50] Re: Androgen Receptor Splice Variant 7 Predicts Shorter Response in Patients with Metastatic Hormone-Sensitive Prostate Cancer Receiving Androgen Deprivation Therapy
Taneja, Samir S.
JOURNAL OF UROLOGY, 2021, 206 (03): : 772 - 772

← 1 2 3 4 5 →